Atopic Dermatitis (AD) BTX 1204 - update from Argo below based on a call they had wth Matt this morning: "The number of patients enrolled for the AD phase 1B trials is double that of the acne trial and includes double blind and placebo, we consider this to be highly relevant. Botanix have a level of confidence with CBD (using the Permetrex delivery system) and its efficacy on reducing inflammation. The AD trial results will be available late April." Sounds like everything is on track, as we've come to expect from Matt and Co
Add to My Watchlist
What is My Watchlist?
